| |
| |
|
| Insider
Information: |
Agarwal Sunil |
| Relationship: |
|
| City: |
Novato |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
1,559,136 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$374,302 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,559,136 |
|
|
| Total
Value |
$374,302 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ultragenyx Pharmaceutical Inc |
RARE |
|
2016-08-19 |
9,136 |
2014-08-19 |
0 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
President of R & D |
2018-03-05 |
0 |
2017-04-13 |
0 |
Premium* |
|
|
Sana Biotechnology, Inc. |
SANA |
|
2021-09-16 |
1,550,000 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
39 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2014-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,400 |
29,400 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2016-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
11,611 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
President of R & D |
• – – |
2017-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
96,627 |
96,627 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
President of R & D |
• – – |
2017-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
35,893 |
120,442 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
President of R & D |
• – – |
2018-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
29,135 |
149,577 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-08-20 |
4 |
AS |
$107.30 |
$1,892,212 |
D/D |
(17,020) |
16,900 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-09-22 |
4 |
AS |
$109.51 |
$54,536 |
D/D |
(498) |
15,858 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-10-20 |
4 |
AS |
$85.51 |
$55,496 |
D/D |
(649) |
14,817 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-11-23 |
4 |
AS |
$95.88 |
$47,748 |
D/D |
(498) |
13,775 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-12-22 |
4 |
AS |
$114.81 |
$57,175 |
D/D |
(498) |
13,231 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2016-01-20 |
4 |
AS |
$72.83 |
$42,606 |
D/D |
(585) |
12,190 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2016-02-22 |
4 |
AS |
$63.48 |
$41,770 |
D/D |
(658) |
10,650 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2016-03-22 |
4 |
AS |
$61.45 |
$39,943 |
D/D |
(650) |
9,608 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2016-04-20 |
4 |
AS |
$70.53 |
$45,774 |
D/D |
(649) |
8,567 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2016-05-24 |
4 |
AS |
$66.00 |
$42,900 |
D/D |
(650) |
7,111 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2016-06-20 |
4 |
AS |
$54.16 |
$35,204 |
D/D |
(650) |
10,569 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2016-07-21 |
4 |
AS |
$52.68 |
$34,189 |
D/D |
(649) |
9,528 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
President of R & D |
• – – |
2017-10-02 |
4 |
AS |
$44.76 |
$326,088 |
D/D |
(7,285) |
84,549 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
EVP, Head of Development & CMO |
• – – |
2021-09-15 |
4 |
AS |
$26.07 |
$1,521,755 |
D/D |
(58,373) |
1,551,627 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
EVP, Head of Development & CMO |
• – – |
2021-09-16 |
4 |
AS |
$26.00 |
$42,302 |
D/D |
(1,627) |
1,550,000 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-08-19 |
4 |
D |
$116.99 |
$641,105 |
D/D |
(5,480) |
23,920 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-09-19 |
4 |
D |
$129.91 |
$70,671 |
D/D |
(544) |
16,356 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-10-19 |
4 |
D |
$88.94 |
$34,864 |
D/D |
(392) |
15,466 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Chief Medical Officer |
• – – |
2015-11-19 |
4 |
D |
$97.71 |
$53,154 |
D/D |
(544) |
14,273 |
0 |
- |
|
39 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
